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A B S T R A C T   
Introduction: The bidirectional connection between the brain and the gut within psychiatric entities has gained 
increasing scientific attention over the last years. As a regulator of intestinal permeability, zonulin acts as a key 
player on the interface of this interplay. Like several psychiatric disorders, intestinal permeability was associated 
with inflammation in previous findings. 
Methods: In this study we explored differences in zonulin serum levels in currently depressed (n = 55) versus 
currently euthymic (n = 37) individuals with an affective disorder. Further, we explored sex differences and 
possible influences on zonulin and affective symptoms like medication, age, body mass index, and smoking 
status. 
Results: Serum zonulin was significantly higher in females than in men independent from affective status (z =
-2.412, p = .016). More specifically, females in the euthymic subgroup had higher zonulin levels than euthymic 
men (z = -2.114, p = .035). There was no difference in zonulin serum levels in individuals taking or not taking a 
specific psychopharmacotherapy. We found no correlation between zonulin serum levels and depression severity. 
Discussion: Increased serum zonulin levels as a proxy for increased intestinal permeability in women may indicate 
a state of elevated susceptibility for depression-inducing stimuli.   
1. Introduction 
The bidirectional connection between brain and gut has developed 
into a field of high scientific interest over the last years. The gut is not 
only responsible for digestion as it possesses millions of neurons as well 
as substantial parts of the immune system and affects emotional and 
cognitive processes (Bonaz et al., 2018). Not only stress-related changes 
in bowel movement – and therefore alterations in gut microbiota 
composition – via the hypothalamus-pituitary-adrenal (HPA) axis, but 
also effects of the gut on central nervous signaling could be shown. The 
mechanisms by which these influences are exerted include vagal stim-
ulation, release of inflammatory and anti-inflammatory compounds, and 
modification of intestinal permeability, and therefore, concentrations of 
circulating agents in the bloodstream (Bonaz et al., 2013). Inflammatory 
processes are known to be involved in the etiology of affective disorders 
as unipolar depression and bipolar disorder. The enormous socio-
economical influence of these diseases is not only highlighted by annual 
treatment costs for unipolar depression exceeding 4,5 billion euros in 
Germany alone (Friemel et al., 2005) but is also represented by a 
shortening of life expectancy between 10 and 15 years for bipolar dis-
order and unipolar depression (Kessing et al., 2015, Laursen et al., 
2016). 
Within the gut, its microbial colonization, the so-called gut micro-
biota, has gained increasing attention in the last years. It interacts with 
and influences our body’s immune system, digestion and nutrition 
regulation (Michielan and D’Inca, 2015). In addition, recent research 
suggests that microbiota were found to be associated with microglial 
function, behavior, affect, motivation and cognitive functions in animals 
as well as in individuals with and without psychiatric diseases (Ait--
Belgnaoui et al., 2014, Alam et al., 2017, Frohlich et al., 2016, Hoban 
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et al., 2017, Lowry et al., 2016, Painold et al., 2019). 
These findings highlight the importance of the intestinal mucosal 
barrier as a regulating interface to this highly active and interacting 
(eco-)system. This barrier is formed by epithelial cells and a mucus layer 
(Madara, 1998). These cells are conjunct via tight junctions which 
prevent and control paracellular passing of agents. In contrast to the 
former assumption that tight junctions are impenetrable, they are now 
understood as a complex interacting system of proteins, which regulates 
intestinal permeability (Turner, 2009). Fasano et al. (Fasano et al., 
2000) discovered pre-haptoglobin 2 as the first member of a family of 
structurally and functionally related endogenous proteins, which they 
named zonulin (Fasano, 2020), with the ability to open tight junctions 
and to consecutively increase intestinal permeability. Another member 
of this family is properdin (Scheffler et al., 2018). Zonulin is synthesized 
by the intestinal mucosa and exerts its loosening effect on tight junctions 
through internalization and subsequent actin polymerization (Fasano 
et al., 1991, Fasano, 2011). It is therefore a key element in paracellular 
permeability (see Fig. 1). 
In line with the assumption that inflammatory processes increase 
intestinal permeability and are involved in the pathogenesis of depres-
sion, a recent study could show that psychological stress in healthy 
subjects led to an increase of paracellular permeability in the small in-
testine (Vanuytsel et al., 2014), allowing the suggestion that zonulin 
might be involved in the mechanism through which this effect is 
mediated. Proinflammatory cytokines like tumor-necrosis-factor α and 
interferon γ may cause an increase in intestinal permeability (Turner, 
2009, Zufferey et al., 2009). This may lead to the perpetuation of a 
process in which agents and possible toxins pass the intestinal barrier 
unregulated, causing an inflammatory response which, in turn, causes 
the further disintegration of the intestinal barrier, resulting in a vicious 
circle (Fasano, 2011). Interestingly, alterations in intestinal perme-
ability in type-1-diabetes were shown prior to the onset of autoimmune 
disease activity in humans as well as in an animal model (Carratu et al., 
1999, De Magistris et al., 1996, Meddings et al., 1999). This led to the 
hypothesis that inflammatory activity might be rather a consequence of 
intestinal barrier deregulation than its cause. 
These findings led to the consideration of potential triggers of zon-
ulin activation within the gut. Fasano et al. identified not only gluten but 
also small intestinal bacteria exposure as potent stimuli for zonulin 
secretion (El Asmar et al., 2002, Fasano et al., 2000). The finding of 
dysbiosis in stool samples of coeliac disease patients by De Palma et al. 
(De Palma et al., 2010) further highlighted the role of dysbiosis and 
microbial interaction with the zonulin regulation system. Beside this, 
zonulin levels were found to be associated with age and body mass index 
(BMI) (Del Chierico et al., 2018, Qi et al., 2017). 
Intestinal permeability is not only negatively influenced by microbial 
presence, though. Improvements in barrier integrity mediated by pro-
biotic bacteria were shown both in human and animal models 
(Ulluwishewa et al., 2011). Pediatric Crohn’s disease patients receiving 
a probiotic for six months showed significantly reduced intestinal 
permeability (Gupta et al., 2000). This effect may be due to an increase 
of tight junction protein expression, which was shown in human cell 
cultures treated with probiotics and probiotic metabolites (Anderson 
et al., 2010, Ewaschuk et al., 2008). 
Moreover, several neuropsychiatric disorders, like autism spectrum 
disorder, were shown to be associated with disruption of intestinal 
permeability (de Magistris et al., 2010). In retrospect, indications for the 
involvement of intestinal barrier impairment in schizophrenia date back 
to the 1950s (Julio-Pieper et al., 2014). Further, zonulin was associated 
with butyrate-producing gut bacteria in a sample containing women 
with anorexia nervosa (Mörkl et al., 2018). 
Zonulin activity may exert an influence on the central nervous sys-
tem through two main mechanisms. The first is through regulation of the 
intestinal barrier alone, allowing metabolites and microbiota to access 
enteric neurons which in turn may lead to vagal afference stimulation. 
This stimulation happens through short chain fatty acids, metabolites 
produced by some microbiota, or indirectly through toll-like-receptor 
mediation (Bonaz et al., 2018). Consecutively, afferent vagal firing is 
suspected to alter central nervous neurotransmitter concentrations 
(Ressler and Mayberg, 2007), constituting the last link of the chain 
through which microbiota exert central nervous influences. The second 
mechanism consists of loosening of the intestinal barrier, allowing 
translocation of microbiota and potentially harmful agents into the 
systemic bloodstream. By additional alteration of the 
blood-brain-barrier, zonulin may be directly involved in the crossing of 
systemic agents into the central nervous system, allowing them to exert 
their influence on the brain after also passing the blood-brain barrier. Its 
potential role in the regulation of blood-brain-barrier permeability is 
depicted in Fig. 2. 
Arguments for this consideration are the high similarity in molecular 
composition between tight junctions of the gut epithelial and the blood- 
brain-barrier (Daneman and Rescigno, 2009) as well as the identifica-
tion of zonulin receptors within the human brain (Lu et al., 2000). 
Despite the knowledge that disruption in intestinal permeability may 
be involved in the development and perpetuation of psychiatric disor-
ders, there is a lack of knowledge in this field. There are, to our 
knowledge, no studies measuring zonulin as a discriminating factor in 
mood disorders as well as in dependence of acute mood symptoms. 
Furthermore, there is a lack of literature regarding potential interactions 
between zonulin and psychopharmacological treatment in psychiatric 
entities. Antipsychotics were associated with changes in the gut micro-
biome (Bahr et al., 2015). Further, anti-inflammatory properties could 
be shown for several antipsychotics (Haring et al., 2015) and antide-
pressants (Kenis and Maes, 2002, Kubera et al., 2001). Considering this, 
Fig. 1. Role of zonulin in the intestinal barrier. 
Note. Secretion of zonulin opens tight junctions, allowing luminal bacteria and 
metabolites to enter the bloodstream (own depiction). 
Fig. 2. Potential role of zonulin in blood-brain-barrier regulation. 
Note. Zonulin may influence blood-brain-barrier integrity through loosening of 
tight junctions (own depiction). 
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possible interactions of these medications and the zonulin regulation 
system could be expected. 
We hypothesized that current mood symptoms were significantly 
positively associated with zonulin in our sample. In the present proof of 
principle study, we therefore determined and compared the levels of 
zonulin concentration in fasting blood in individuals with affective 
disorders. We divided the group into currently euthymic and currently 
depressed individuals. We further explored differences in zonulin serum 
levels within patients currently taking antidepressants and antipsy-
chotics and those without. Additionally, we divided the affective sub-
groups by sex. Furthermore, we associated zonulin levels with current 
affective symptoms. The main hypothesis was that euthymic individuals 
have lower zonulin levels compared to unipolar and bipolar depression. 
2. Methods 
Subjects were in- and out-clinic patients of the Department of Psy-
chiatry and Psychotherapeutic Medicine of the Medical University Graz, 
Austria. Exclusion criteria were inability for informed consent, age 
under 18, severe addiction (alcohol, benzodiazepines, morphines), se-
vere affective episode (Hamilton Depression Scale (Hamilton, 1960) 
(HAMD) > 30), severe brain organic disease (epilepsy, brain tumor), 
status post severe traumatic brain injury or brain surgery, known ma-
lignancy, intellectual disability, dementia (Mini Mental Status < 20), 
severe autoimmune disease or immunosuppression, chronic laxative 
abuse, acute infectious diarrhea, antibiotic treatment within the last 
month, and regular intake of probiotic or butyrate-containing dietary 
supplements. 
All participants included took part in a study approved by the local 
ethics committee of the Medical University of Graz (EK-number EK- 28- 
413 ex 15/16; EK- 28-413 ex 15/16; EK 29-235 ex 16/17). All subjects 
gave written informed consent before being enrolled. 
Afterwards, fasting blood was collected between 08:00 and 09.00 a. 
m. either on the same or the following day and immediately frozen and 
stored at -80◦Celsius. Participants underwent a clinical interview to 
assess potential comorbidities and previous course of disease as well as 
anthropometric data. Furthermore, cognitive testing was performed, 
and subjects filled out questionnaires concerning current and previous 
medication, and other factors relevant for the disorder like lifestyle and 
hereditary background. Psychiatric diagnosis of bipolar disorder or 
unipolar depression was evaluated by a psychiatrist using the Mini In-
ternational Neuropsychiatric Interview (MINI) (Sheehan et al., 1998). 
Additionally, mood assessment via the HAMD was performed. 
Zonulin concentration was measured with the IDK® Zonulin ELISA 
assay from Immundiagnostik AG (Bensheim, Germany). Briefly, samples 
were incubated with a biotinylated Zonulin family peptide (ZFP) tracer. 
In the second incubation step, peroxidase-labelled streptavidin binds to 
the biotinylated ZFP tracer. Following a washing step to remove un-
bound components the peroxidase substrate tetramethylbenzidine was 
added. Then the enzyme reaction was stopped by the addition of acid. 
The resulting chromogenic compound was measured photometrically at 
450 nm. The intensity of the color was inversely proportional to the 
concentration of the measured analytes. 
All statistical analysis was performed using SPSS 25, the level of 
significance was set to p < .05. As data was not parametric, group 
comparisons were done with the Mann-Whitney-U test, while correla-
tions were performed using Spearman correlation. 
3. Results 
Study participants were divided into two different groups according 
to their current state of mood (euthymic or depressed) at the time of 
inclusion in the study. We used the HAMD score to distinguish between 
currently euthymic individuals (HAMD < 10) and those with currently 
mild to moderate depression (HAMD 10 - 30). Our sample consisted of 
121 subjects, with 45 individuals considered euthymic and 76 
considered depressed. Further group characteristics can be found in 
table 1. 
Groups did not differ significantly regarding sex (z = -1.480, p =
.139), current use of antipsychotic medication (z = -1.201, p = .230), 
current use of antidepressants (z = -1.587, p = .112), and smoking status 
(z = -.257, p = .797). 
There was a significant difference between groups regarding HAMD 
(z = -9.182, p <.001), age (z = -2.068, p = .039), and BMI (z = -2.944, p 
= .003). Euthymic individuals displayed higher age and BMI but lower 
HAMD scores. 
We found no significant difference in zonulin serum levels between 
the groups (z = -.950, p = .342). 
Further, we found no difference in zonulin serum levels between 
subjects currently taking antipsychotic medication and those without, 
neither in the whole sample (N = 92, z = -.325, p = .745) nor in the 
euthymic (N = 36, z = -.127, p = .900) and depressed (N = 56, z = -.459, 
p = .647) subgroups. 
There was no significant difference serum zonulin levels between 
individuals currently taking antidepressants and those without, neither 
in the whole sample (N = 92, z = -.855, p = .393), nor in the euthymic 
(N = 36, z = -.420, p = .674) and depressed (N = 56, z = -.260, p = .795) 
subgroups. 
Independent of affective subgroup, we found zonulin to be signifi-
cantly higher in women compared to men within the whole sample (N =
93, z = -2.412, p = .016). Women also displayed higher zonulin serum 
levels than men in the euthymic subgroup (N = 37, z = -2.114, p = .035). 
There was no significant difference in zonulin concentration between 
sexes in the depressed subgroup (N = 56, z = -.833, p = .405). 
We found no significant correlation between HAMD and zonulin 
serum levels within our sample (N = 93, p = .479) or in the affective 
subgroups (euthymic, N = 37, p = .324; depressed, N = 56, p = .377). 
4. Discussion 
The aim of our study was to determine, whether serum zonulin, as a 
marker of intestinal permeability, was elevated in currently affective 
states of subjects with affective disorders compared to euthymia. 
Further, we aimed to create knowledge regarding the role of previously 
described influences on zonulin concentrations in the interaction be-
tween this biomarker and the course of affective disorders. Lastly, we 
explored the relation between psychopharmacological treatment and 
zonulin as well as sex differences for zonulin in our sample. 
We found no significant difference in serum zonulin levels between 
euthymic and depressed individuals with bipolar disorder or unipolar 
depression. Furthermore, we found no significant difference in zonulin 
serum levels between subjects taking antipsychotic medication and 
those currently without. Additionally, there was no significant 
Table 1 
Group description.   
Euthymic (n = 37) Depressed (n = 55)  
M (+/- SD) M (+/- SD) 
















Sex: female [%] 37.80 25.00 
Smoking: yes [%] 42.90 45.30 
Antipsychotics: yes [%] 50.00 38.70 
Antidepressants: yes [%] 70.50 82.90 
Bipolar Disorder: yes [%] 81.10 14.30 
Abbreviations: M: mean, SD: standard deviation, BMI: body mass index, HAMD: 
Hamilton Depression Scale. 
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correlation between depressive symptom severity and serum zonulin 
levels. These findings, at first, appeared inconclusive. When considered 
with pre-existing literature, however, our findings fit in with the current 
scientific discourse. There are contradictory and inconsistent reports on 
zonulin and its role within psychiatric entities. A recent study found 
zonulin to be decreased in depressed individuals who had recently 
attempted suicide, even though another marker for intestinal perme-
ability, the intestinal fatty acid binding protein (FABP) was elevated in 
this subgroup. Moreover, zonulin correlated negatively with interleukin 
6, a pro-inflammatory cytokine in this study (Ohlsson et al., 2019). 
Another recent study found both zonulin and FABP to be elevated in 
patients with depression and anxiety compared to healthy controls 
(Stevens et al., 2018). Mechanisms tightly intertwined with perme-
ability regulation are immunity and inflammation. There already are 
several inflammatory diseases for which an association with intestinal 
permeability and zonulin could be shown, including inflammatory 
bowel disease, rheumatoid arthritis, coeliac disease, type-1-diabetes, 
multiple sclerosis, and schizophrenia (De Palma et al., 2010, 
Edwards, 2008, Fasano, 2008, Fasano, 2011, Mäkelä et al., 2006, 
Ochoa-Reparaz et al., 2009). Still, the heterogeneity and inconsistency 
in results concerning the role of zonulin in intestinal permeability 
changes due to inflammatory processes, highlights the need for further 
research to create a deeper understanding of its implication. It was hy-
pothesized that a zonulin-mediated opening of the intestinal barrier may 
represent a defense mechanism to flush out microorganisms (El Asmar 
et al., 2002), but findings of bacterial translocation and endotoxins in 
the bloodstream provide arguments for the involvement of intestinal 
barrier decrease in the pathophysiology of several entities (Carratu 
et al., 1999, Fasano et al., 1991, Forsyth et al., 2011, Maes et al., 2008, 
Maes et al., 2012). 
Our finding that serum zonulin was significantly higher in women 
with bipolar and unipolar depression during euthymia is potentially 
intriguing. Given the higher prevalence of unipolar depression among 
women (Möller et al., 2011), one might speculate as to what extent 
zonulin might be involved in a possible explanation for this sex differ-
ence. One might speculate, that increased permeability may pose a state 
of elevated susceptibility for depression-inducing stimuli. Regarding this 
hypothetical concept, zonulin’s possible effect on the 
blood-brain-barrier is of special interest. The identification of zonulin 
receptors in human brain tissue (Lu et al., 2000) underpinned the hy-
pothesis that zonulin may not only act as a regulator of intestinal 
permeability but could also influence passage through other epithelial 
barriers. 
Disruption of blood-brain-barrier function was shown for brain 
edema, brain tumor, traumatic brain injury and multiple sclerosis (Lu 
et al., 2000). For the latter, an elevation of zonulin serum levels in pa-
tients with relapsing remitting and secondary progressive multiple 
sclerosis compared to controls could be shown (Waubant, 2006). Al-
terations of serum zonulin in women were described in several publi-
cations before (Demir et al., 2019, Mörkl et al., 2018), but our study is, 
to our best knowledge, the first report of a sex difference in affective 
disorder patients. For depression and anxiety, data regarding intestinal 
permeability is sparse to date. Maes et al. (2008) found elevated lipo-
polysaccharide antibodies in depressed patients, suggesting an 
inflammation-associated impairment of the intestinal barrier. They later 
could confirm their results, when they found lipopolysaccharide anti-
bodies to be higher in depressed patients than in healthy controls, with 
chronically depressed subjects showing the highest serum levels (Maes 
et al., 2012). Research on psychological stress showed an association 
between stress and relapse in patients with Crohn’s disease, which is 
characterized by deregulated intestinal permeability (Camara et al., 
2009). Still, further research to assess zonulin’s potential role in 
blood-brain-barrier regulation, especially in women, is needed. 
5. Limitations 
An important limitation to our results is the fact that the euthymic 
subgroup was significantly older and had a higher BMI than currently 
depressed individuals. Both parameters were shown to be associated 
with elevated zonulin levels in previous publications (Del Chierico et al., 
2018, Qi et al., 2017). Within our sample, however, we found no sig-
nificant association between age (p = .704), BMI (p = .171) and serum 
zonulin. Another limitation is the overrepresentation of men within our 
sample (N = 88). However, subgroups did not differ significantly 
regarding sex distribution (z = -1.537, p = .124). Further, our sample 
consisted of subjects suffering from either unipolar or bipolar depres-
sion. Still, bipolar and unipolar subjects did not differ regarding zonulin 
levels (z = 1.016, p = 0.310). To shed some light on the implications of 
zonulin for different psychiatric entities, further studies using matched 
samples to compare subjects suffering from bipolar disorder and major 
depression. The lack of healthy controls is an important weakness of our 
study. As this was a proof of principle study, further research, comparing 
our findings to a healthy cohort, is necessary. Lastly, the cross-sectional 
design of our study allows no interpretation of potential changes of 
zonulin in the course of disease. 
6. Conclusion 
Epithelial permeability poses an interesting potential factor in 
neuropsychiatric entities. Further research should aim to evaluate the 
therapeutic potential of epithelial barrier amelioration. The role of 
zonulin as a valid biomarker in affective disorders remains unclear due 
to partly inconclusive findings. Future research should focus on the 
comparison of zonulin with other promising biomarkers like FABP. To 
assess time-dependent dynamics in the interaction of those biomarkers 
and the course of disease, longitudinal study designs should be 
preferred. 
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